The HK1 Knockout Jurkat Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of Jurkat cells carrying a targeted disruption of the HK1 gene, which encodes hexokinase 1. As a polyclonal knockout pool, this product provides a heterogeneous loss-of-function model without clonal selection, enabling robust analysis of HK1 deficiency in a T-cell leukemia background. The cells are suitable for investigating the role of the rate-limiting glycolytic enzyme in cancer metabolism, apoptosis, and cellular energy homeostasis.
The parental Jurkat cell line is an immortalized human T-lymphocyte model derived from an acute T-cell leukemia patient. These cells are extensively used in immunological research to study T-cell receptor signaling, cytokine production, and apoptotic pathways. Their leukemic origin and characteristic dependence on aerobic glycolysis (the Warburg effect) make them a relevant system for examining metabolic vulnerabilities in hematological malignancies.
HK1 catalyzes the phosphorylation of glucose to glucose-6-phosphate, the first and rate-limiting step of glycolysis. Its expression is transcriptionally regulated by HIF-1?? and c-Myc, and its activity is stimulated by AKT-mediated signaling downstream of insulin and growth factor pathways. In addition to its cytoplasmic glycolytic role, HK1 binds to the mitochondrial outer membrane via interactions with VDAC1 and VDAC2, forming a complex that couples glucose metabolism to mitochondrial function and apoptosis regulation. This interaction competitively influences Bcl-2 family protein binding, modulating apoptotic sensitivity. Representative downstream effectors include glucose-6-phosphate, glycolytic intermediates, and reactive oxygen species, while pathway components such as PFK, PKM2, LDHA, and GLUT1 coordinate further metabolic flux.
Disruption of HK1 in Jurkat cells profoundly impacts glycolytic flux, leading to reduced glucose utilization, lactate production, and ATP generation through glycolysis. The loss of mitochondrial HK1-VDAC association may disrupt the metabolic checkpoint at the outer mitochondrial membrane, potentially altering mitochondrial membrane potential and sensitizing cells to apoptotic stimuli. This knockout model thus provides a powerful tool to dissect the metabolic reprogramming that supports T-cell leukemia survival and proliferation, and to examine the interplay between glycolysis and apoptosis in a relevant immunological context.
Typical applications include investigating the role of glycolysis in T-cell leukemia metabolism using assays such as hexokinase activity measurements, glucose uptake (2-NBDG), lactate production, and Seahorse metabolic flux analysis. The cells are also ideal for apoptosis mechanism studies, assessed by Annexin V/7-AAD staining and mitochondrial membrane potential dyes, and for validating pharmacological inhibitors targeting hexokinase or downstream glycolytic enzymes. Furthermore, this knockout model enables exploration of how metabolic shifts influence T-cell function, proliferation, and response to therapeutic agents. For further information, please contact Ascent Research.
